Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE:MTEC), a leading business technology company in the cannabis space, is pleased to announce that its premiere cannabis education platform, Cannvas.me will be offered through a physical device in medical and related clinics. Patients and medical professionals will have access to a low cost, application specific, hand held device to learn about the benefits of health and wellness through cannabis and to access information specific to their needs.

“Through discussions with medical professionals, the need for education at the point of treatment was clearly evident,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “Our solution is to have a physical device specific to medical cannabis education and information in medical and related clinics. Our goal is to quickly expand our offering to every clinic across Canada and friendly jurisdictions around the world. Throughout the development of Cannvas.me this has been taken into consideration while rolling out the landscape of integration with potential clinic partners. With the Cannvas.me platform launch quickly approaching, we are in a position to accelerate those conversations and convert them into integrated educational delivery partners.”


Through widespread medical clinic integration, medical patients will be able to access the Cannvas.me education platform at the source of their treatment: medical and related clinics. Access to trusted information is important for both the patient and the prescribing medical professional. Due to the lack of available information, medical professionals have been reluctant to prescribe cannabis in its many forms. By providing information at the source of treatment, it will give the patient peace of mind by looking at all alternatives and doctors the confidence to write the suitable prescriptions for the specific ailments.

Cannvas is currently in the final stages of partnership integration protocols and revenue share guidelines, which would be utilized with our potential partners. Cannvas has set aggressive expansion targets which we feel are achievable through current discussions with existing networks worldwide.

Cannvas also announces that it has issued an aggregate of 3,500,000 common shares (the “Shares”) of the Company at a deemed value of $0.35 per Share to Shawn Moniz, CEO and a director of the Company, and Steve Loutskou, COO and a director of the Company, pursuant to the achievement of certain milestones and in accordance with their respective consulting agreements.

About Cannvas.me

Cannvas.me is an innovative and unbiased online health sciences educational platform where patients can take an active role in defining the path of control of their health and wellness through the use of cannabis. It is a scalable and comprehensive solution for the global cannabis community offering interactive tools and physician-backed content. It takes an innovative approach to place cannabis education at the forefront by bringing design, creativity, data aggregation and global connectivity to new heights. Through subsidiaries Cannvas Creative, Cannvas Data and Cannvas Connect; Cannvas.me will feature innovative tools such as educational learning modules in its Cannvas University, an interactive Cannvas Strain Matcher that educates audiences with specific ailments, and Cannvas Culinary, for those wishing to learn about the culinary approach to treatments.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Click here to connect with Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE:MTEC) for an Investor Presentation. 

(TheNewswire)

Keep reading... Show less

Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products

Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.

Keep reading... Show less

Further to its press release dated April 12, 2021, Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that it has oversubscribed and upsized its non-brokered private placement (the “Offering”) due to strong investor demand. The Company now anticipates that the Offering will be completed for gross proceeds of not less than $550,000.00, consisting of not less than 2,910,053 units (“Units”) at a price of $0.189 per Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one Common Share purchase warrant (a “Warrant”). Each Warrant is exercisable to acquire one Common Share at an exercise price of C$0.38 per Common Share for a period of 36 months from the date of closing of the Offering (the “Closing Date”), scheduled for April 22, 2021. The Units will have a hold period of four months and one day from the date of issuance.

Ayurcann CEO Igal Sudman commented: “We are very pleased with the demand we are seeing for the Offering. The feedback we have received to date is showing that our business is resonating with investors. We’re looking forward to closing the offering and proceeding with the planned Phase 2 build out, which will help greatly increase our facility’s capacity.”

Keep reading... Show less

UK InstaCoin APP Promises to Open NFTs up to the Masses through Social Media

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on its recent investment in InstaCoin Technologies Ltd., a newly formed UK entity

Keep reading... Show less

Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.

The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.

Keep reading... Show less